08 September 2022
Business Update and Interim Report for the six months ended 30 June 2022
Shield Therapeutics plc (LSE: STX), reports its unaudited interim results for the first half of 2022 (H1:2022) and provides a business update.
July marked the one-year anniversary of the US launch of Accrufer®. Over the last twelve months, Shield has built a high-performance executive leadership team and launch-savvy commercial organisation. The Company has developed and implemented a new US commercial strategy and launch plan, secured broad reimbursement coverage across Commercial and Medicaid segments, substantially increased prescriber awareness and expanded the global Accrufer® opportunity through a series of new, high-value commercial partnerships.
For further details click here